An observational study in Moderate Respiratory Distress and Severe Respiratory Distress, sponsored by Epicentre. Not yet recruiting at 1 site in Afghanistan. Open to participants aged 1 Month to 5 Years. Per ClinicalTrials.gov, last updated 2025-01-30.
Sponsored by Epicentre · Observational
The purpose of this study is to prospectively evaluate the process of implementing HFNO in several MSF projects, varying according to geographical and programmatic contexts, population, health structures, human resources, and management. It will generate evidence on the operational feasibility (in terms of human resources, equipment, logistics and costs) of integrating HFNO into PICU standard of care, as well as on the users' and caregivers' perspectives on HFNO and on the children clinical outcomes observed where HFNO is implemented. This relevant information will guide MSF in the decision making of scaling up HFNO therapy in its projects.
Mixed method study: quantitative component for the data of the children and qualitative data for the perception for health staffs and parents
894 studies on the registry are indexed under Dyspnea; 189 are open to participants now.
This study's planned enrollment of 960 is above the median of 106 across 272 observational studies indexed under Dyspnea.
Browse Dyspnea studies →Epicentre is the lead sponsor of 49 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
MSF pediatric ICU in 4 sites (Herat- Afghanistan, Kenema- Sierra Leone, Goyalmara hospital for Rohingya refugee - Bangladesh, Khamir- Yemen)
Inclusion Criteria:
Prescription of HFNO therapy
Recovery with SPO2 above 92%
Time frame: From enrollment to day 3 to 10
Acceptability, feasibility and perception from the caretaker point of view
interview of the caretaker
Time frame: 2 weeks after hospitalisation
Acceptability, feasibility and perception from the health staff point of view
Interview of the health staffs (doctors, nurses, biomed, managers, logisticians)
Time frame: From Month 2 until Month 12
Plan to share: Yes — Based on the data sharing policy of MSF
Supporting information: Clinical study report
No publications or documents are linked to this record.
Start is estimated for Jan 2025; primary completion for Dec 2025, 11 months later.
Of 116 non-industry observational studies under Dyspnea, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 11 months is below that.
Counting every sponsor, half of 125 studies reached it within 24 months; a quarter within 11 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Epicentre